Biphenotypic Sinonasal Sarcoma: Clinicopathologic Features in 16 Patients
Journal of Neurological Surgery Part B: Skull Base · 01.02.2024 · 85 (S 01 S 01) · S1-S398
DOI: 10.1055/s-0044-1779984 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurological Surgery Part B: Skull Base, erschienen am 01.02.2024. Verfasst von Brian P. Hall und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Biphenotypic sinonasal sarcoma (BSNS) is an extremely rare malignancy with limited clinical experience or data on treatment outcomes. This descriptive series reports clinicopathological characteristics and treatment outcomes of a series of patients with BSNS evaluated and/or treated at our institution.
Methods
We queried our institutional pathology database to identify all patients diagnosed with BSNS. Clinical, pathologic, treatment, and follow-up data were retrospectively abstracted from the medical record.
Results
We identified a cohort of 16 patients diagnosed between 2013 and 2021, which included 15 females and 1 male with an average age of 48 years. Nine patients underwent management within our institution, of whom 7 were Black. The remaining 7 patients had undergone pathology review of external cases. Of the 9 patients with complete clinical information, all tumors involved the nasal cavity or ethmoid sinuses with 6 demonstrating bone invasion on pathology. Involvement of the orbit (2), cribriform plate (1), and intracranial extension (2) were noted. There were no instances of perineurial invasion or lymphovascular space invasion on pathology. All patients managed at our institution underwent surgical resection and 6 of 9 received adjuvant radiotherapy. Radiation modalities included both photon (4) and proton (2) therapy. The median radiation dose was 60 Gy in 30 fractions. One patient received 74 Gy in 37 fractions for gross residual disease. None received chemotherapy. At a median follow-up time of 3.4 years, no patients have experienced local recurrence or progression. None have experienced regional or distant metastases and all patients remained alive at last follow-up. Immunomarker and FISH analysis results were consistent with those reported in existing case studies. Positive immunomarkers included S-100 (15 patients), SMA (15 patients), EMA (5 patients), Desmin (9 patients), and beta-catenin (4 patients). Negative immunomarkers were observed in 9 patients for SOX-10 and 6 for AE1/3. FISH analysis revealed 3 of 16 patients had a positive PAX3-MAML3 rearrangement, while 6 were negative for database fusions. One patient had a variant in the SYT gene, while others yielded inconclusive or uninterpretable results.
Conclusion
Our institutional experience with this rare disease confirms a strong female predominance and a young age. While some reports have suggested a fairly high propensity for local recurrence in this disease, among the 9 patients treated at our institution, all maintain disease control, suggesting an indolent disease course. Publication History Article published online: 05 February 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Zitieren
APA
Hall, B. P., Anderson, J. L., Rivera, C. S., Henriquez, O. A., DelGaudio, J. M., McDonald, M. W., & Magliocca, K. R. (2024). Biphenotypic Sinonasal Sarcoma: Clinicopathologic Features in 16 Patients. Journal of Neurological Surgery Part B: Skull Base, 85(S 01 S 01), S1-S398. https://doi.org/10.1055/s-0044-1779984
Vancouver
Hall BP, Anderson JL, Rivera CS, Henriquez OA, DelGaudio JM, McDonald MW, et al. Biphenotypic Sinonasal Sarcoma: Clinicopathologic Features in 16 Patients. Journal of Neurological Surgery Part B: Skull Base. 2024;85(S 01 S 01):S1-S398. doi:10.1055/s-0044-1779984
BibTeX
@article{Hall2024,
author = {Hall, Brian P. and Anderson, Joshua L. and Rivera, Clementino Solares and Henriquez, Oswaldo A. and DelGaudio, John M. and McDonald, Mark W. and Magliocca, Kelly R.},
title = {Biphenotypic Sinonasal Sarcoma: Clinicopathologic Features in 16 Patients},
journal = {Journal of Neurological Surgery Part B: Skull Base},
year = {2024},
volume = {85},
number = {S 01 S 01},
pages = {S1--S398},
doi = {10.1055/s-0044-1779984}
}
EUVIMED